NYXH Nyxoah

Publication Relating to Transparency Notifications

Publication Relating to Transparency Notifications

                

 REGULATED INFOMATION

Publication Relating to Transparency Notifications

Mont-Saint-Guibert (Belgium), April 20, 2023, 10.30pm CET / 4.30pm ET In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below.

Together Partnership

On April 18, 2023, Nyxoah received a transparency notification from Together Partnership following the crossing of the 10% threshold by Together Partnership on March 30, 2023. As of such date, Together Partnership held 2,948,285 shares, representing 10.42% of the total number of voting rights on March 30, 2023 (28,286,985).

The notification dated April 17, 2023 contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: a person that notifies alone
  • Persons subject to the notification requirement: Together Partnership (with address at Van Putlei 31, 2018 Antwerp)
  • Date on which the threshold was crossed: March 30, 2023
  • Threshold that is crossed: 10%
  • Denominator: 28,286,985
  • Notified details:



A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the

securities
Linked to securitiesNot linked to the

securities
Together Partnership2,503,5002,948,285   10.42% 
 TOTAL2,948,285 0 10.42%0.00%
  • Chain of controlled undertakings through which the holding is effectively held: Together Partnership is not a controlled entity.



 ResMed Inc.

On April 18, 2023, Nyxoah received a transparency notification from ResMed Inc. following the crossing of the 5% threshold by ResMed Inc. on March 30, 2023. As of such date, ResMed Inc. held 1,499,756 shares, representing 5.30% of the total number of voting rights on March 30, 2023 (28,286,985).

The notification dated April 16, 2023 contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: a person that notifies alone
  • Persons subject to the notification requirement: ResMed Inc. (with address at 9001 Spectrum Center Boulevard, San Diego, CA 92123, USA)
  • Date on which the threshold was crossed: March 30, 2023
  • Threshold that is crossed: 5%
  • Denominator: 28,286,985
  • Notified details:



A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to the

securities
Linked to securitiesNot linked to the

securities
ResMed Inc.794,235 1,499,756   
 TOTAL1,499,756 05.30%0.00%
  • Chain of controlled undertakings through which the holding is effectively held: No indirect holding of voting securities. ResMed Inc. is not a controlled entity.



*

* *

Contact:

Nyxoah

David DeMartino, Chief Strategy Officer





Attachment



EN
20/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates.  Preliminary, Unaudited Second Quarter 2025 Financial Results and Business U...

 PRESS RELEASE

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre ...

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025  Mont-Saint-Guibert, Belgique – 11 août 2025, 7h00 CET / 01h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui certains résultats financiers préliminaires non audités pour le deuxième trimestre 2025 et d'autres informations su...

 PRESS RELEASE

Nyxoah Receives Approval from FDA for Genio® System for the Treatment ...

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep ApneaU.S. Commercialization Officially Launched Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food a...

 PRESS RELEASE

Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné...

Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du Sommeil INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du SommeilLancement Officiel de la Commercialisation aux États-Unis Mont-Saint-Guibert, Belgique – 8 juillet 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch